Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB) -- Ignore unavailable to you. Want to Upgrade?

To: William Marsh who wrote (32)	12/13/1997 5:22:00 PM
From: Andy Patton	Respond to of 236

I'm not capable of assessing the science, so bear that in mind, but yes, it looks to me as though Stressgen has advanced in the last year, and therefore would be a better investment now than a year ago even if the stock price were the same (ie $3.50). I'm holding. -Andy Patton

To: William Marsh who wrote (32)	12/13/1997 6:19:00 PM
From: Heat Shock	Read Replies (1) \| Respond to of 236

Bill, I think the problem is impatience. Good news, good publicity, and the stock is in the toilet! Some investors must have been told or found out about SSB's outstanding science, broad platform technology, and glorious prospects. So they put money into SSB thinking they will get a sizable share price increase in a few months. Right. The 2 promising Phase I trials will start maybe in 1Q 1999, a year from now. ONE YEAR. I'm guessing these people are aghast at waiting so long, so they are selling. With volume so low, there is large share price reaction. We're losing our "weak hands" people. I think the market reacts on share price most when the company enters and finishes clinical trials P1, P2 and P3. My own schedule for the pot of gold at the end of the rainbow is the range 2000 -> 2003. With 2 excellent Phase I candidates starting around 1Q 1999, we are on schedule. P1 results would be sometime in 1999 and P2 starting about 4Q 1999 -> 1Q 2000. If SSB is smart, and I thing they are, there ought to be additional clinical trial candidates emerging during 1998, probably at least one in infectious disease. This is the start of a super pipeline- much beloved by biotech investors. I searched for "weak hands" here at SI and found this: exchange2000.com:80/~wsapi/investor/reply-2951665 Also, the timing of the 2 IND announcements is right for SSB to be a good candidate for year end tax loss selling. Heat.